Proteomics for brain disorders - The promise for biomarkers

Annals of the New York Academy of Sciences

Volumn 1180, Issue , 2009, Pages 68-74

  Ward, Malcolm ^a   Güntert, Andreas ^b   Campbell, James ^a   Pike, Ian ^a  

^a Proteome Sciences Plc   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Mass spectrometry; Tandem Mass Tag

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT FACTOR H; ROSIGLITAZONE; TAU PROTEIN;

ALZHEIMER DISEASE; BODY FLUID; BRAIN DISEASE; BRAIN TISSUE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONFERENCE PAPER; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; FREEZE THAWING; HUMAN; IMMUNOASSAY; LIVER INJURY; MASS SPECTROMETRY; PROTEIN MALNUTRITION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BRAIN DISEASES; HUMANS; PROTEOMICS;

EID: 70449378959     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05018.x     Document Type: Conference Paper

References (7)

1. Thompson, A., J. Schäfer, K. Kuhn, et al. 2003. Tandem Mass Tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75: 1895-1904.
2. Anderson, N.L., N.G. Anderson, L.R. Haines, et al. 2004. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res. 3: 235-244.
3. Rogers, M., P. Clarke, J. Noble, et al. 2003. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issuesaffecting potential clinical utility. Cancer Res. 63: 6971-6983.
4. Hye, A., S. Lynham, M. Thambisetty, et al. 2006. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129: 3042-3050.
5. Cutler, P., E. Akuffo,W. Bodnar, et al. 2008. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin. Appl. 2: 467-477.
6. Akuffo, E.L., J.B. Davis, S.M. Fox, et al. 2008. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 13: 618-636.
7. Thambisetty, M., A. Hye, C. Foy, et al. 2008. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J. Neurol. 255: 1712-1720.